Showing results (301-310 of 512) with videos related to

Sort By:
Pageof 52
Journal of the American Academy of Dermatology|September 24, 2018
A provider global assessment quality measure for clinical practice for inflammatory skin disordersAlice Gottlieb, Nicole Salame, April W Armstrong, et al.
JAMA Dermatology|May 26, 2021
Incidence of Venous Thromboembolism in Patients With Dermatologist-Diagnosed Chronic Inflammatory Skin DiseasesMaria C Schneeweiss, Seoyoung C Kim, Richard Wyss, et al.
The Journal of Rheumatology|July 15, 2023
Report of the Skin Research Workgroups From the IDEOM Breakout at the GRAPPA 2022 Annual MeetingMelissa P Zundell, Michael J Woodbury, Kathryn Lee, et al.
The Journal of Rheumatology|April 2, 2022
Report of the Skin Research Working Groups from the GRAPPA 2021 Annual MeetingJenna E Yousif, Joseph F Merola, Lourdes M Perez-Chada, et al.
Frontiers in Medicine|February 13, 2023
Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetesAlexander Egeberg, Joseph F Merola, Knut Schäkel, et al.
Frontiers in Medicine|March 28, 2023
Corrigendum: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetesAlexander Egeberg, Joseph F Merola, Knut Schäkel, et al.
Clinical and Experimental Dermatology|May 11, 2024
Impact of disease, musculoskeletal symptoms and disease control in the CorEvitas Psoriasis RegistryCarly Grant, Lourdes M Perez-Chada, Ryan W Harrison, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 23, 2026
Litifilimab efficacy on skin outcomes in cutaneous lupus erythematosus in the Phase 2 LILAC studyVictoria P Werth, Joseph F Merola, Richard Furie, et al.
Dermatology and Therapy|March 13, 2022
Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic ArthritisBoni E Elewski, Andrew Blauvelt, Gaia Gallo, et al.
Journal of the American Academy of Dermatology|June 1, 2020
Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension studyAndrew Blauvelt, Kim A Papp, Joseph F Merola, et al.
Pageof 52